ПРОФИЛЬ СИМПТОМОВ ПАТОЛОГИЧЕСКОГО ВЛЕЧЕНИЯ ПРИ РАССТРОЙСТВЕ ВСЛЕДСТВИЕ УПОТРЕБЛЕНИЯ «СОЛИ ДЛЯ ВАНН»: КЛИНИЧЕСКИЙ СЛУЧАЙ
“Bath salts” is a term often used to describe a number of novel psychoactive substances (NPS) including synthetic cathinones. The abuse of “bath salts”/synthetic cathinones has recently been observed in Kazakhstan. In the present paper, the case of “bath salts” use disorder in a 20-year-old woman is presented. Patient’s history of substance use met the DSM-5 diagnostic criteria of cathinones-induced disorder. The course of disease was observed for 2 months in the period of post-acute withdrawal in the frame of an inpatient withdrawal unit. During this time, recurrent episodes of craving characterized by heterogeneous severity and symptoms were observed. The emergence of delusional symptoms represented a clinical challenge for differential diagnosis. The case provides the opportunity to discuss the craving profiles possibly associated with the recreational use of cathinones
Mariya V. Prilutskaya1,2, Francesco Saverio Bersani3
1 Semey Medical State University, Semey, Kazakhstan
2 Republican Scientific and Practical Center for Medical and Social Problems of Drug Addiction, Pavlodar, Kazakhstan
3 Sapienza University of Rome, Rome, Italy
1. Baumann M.H., Solis E. Jr., Watterson L.R., Marusich J.A., Fantegrossi W.E., Wiley J.L. Baths salts, spice, and related designer drugs: the science behind the headlines. J Neurosci. 2014, 34(46), pp. 15150-1518.
2. Castaneto M.S. Gorelick D.A., Desrosiers N.A., Hartman R.L., Pirard S., Huestis M.A. Synthetic cannabinoids: epidemiology, pharmacodynamics, and clinical implications. Drug Alcohol Depend. 2014, 144, pp. 12-41.
3. Cinosi E., Martinotti G., Simonato P., Singh D., Demetrovics Z., Roman-Urrestarazu A., Bersani F.S., Vicknasingam B., Piazzon G., Li J.H., Yu W.J., Kapitány-Fövény M., Farkas J., Di Giannantonio M., Corazza O. Following "the Roots" of Kratom (Mitragyna speciosa): The Evolution of an Enhancer from a Traditional Use to Increase Work and Productivity in Southeast Asia to a Recreational Psychoactive Drug in Western Countries. Biomed Res Int., 2015. Available at: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4657101 (accessed 30.01.2016).
4. Corazza O., Schifano F., Parrott A.C. Novel psychoactive substances: first international conference. Hum Psychopharmacol Clin Exp. 2013, 28, pp. 287–288.
5. Diagnostical and Statistical Manual of Mental Disorders – Fifth Edition. Substance-Related and Addictive Disorders. Section II. Arlington, VA, American Psychiatric Association. 2013, pp. 481-590.
6. Hohmann N., Mikus G., Czock D. Effects and risks associated with novel psychoactive substances: mislabeling and sale as bathsalts, spice, and research chemicals. Dtsch Arztebl Int. 2014, 111(9), pp. 139-147.
7. Marlatt G.A. Craving notes. British Journal of Addiction. 1987, 82, pp. 42–44.
8. Martinotti G., Corazza O., Achab S., Demetrovics Z. Novel psychoactive substances and behavioral addictions. Biomed Res Int. 2014. Available at:http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4290894 (accessed 30.01.2016).
9. Parrott A.C. Novel psychoactive substances: second and third international conferences. Hum Psychopharmacol. 2015, 30(4), pp. 209-212.
10. Parrott A.C. Why all stimulant drugs are damaging to recreational users: an empirical overview and psychobiological explanation. Hum Psychopharmacol. 2015, 30(4), pp. 213-224.
11. Sayette M.A., Shiffman S., Tiffany S.T., Niaura R.S., Martin C.S., Shadel W.G. The measurement of drug craving. Addiction. 2000, 95 (l2), pp. 189–210.
12. Simonato P., Corazza O., Santonastaso P., Corkery J., Deluca P., Davey Z., Blaszko U., Schifano F. Novel psychoactive substances as a novel challenge for health professionals: results from an Italian survey. Hum Psychopharmacol. 2013, 28(4), pp. 324-31.
13. Tiffany S.T. Cognitive concepts of craving. Alcohol Research & Health. 1999, 23(3), pp. 215–224.
14. Tiffany S.T., Carter B.L., Singleton E.G. Challenges in the manipulation, assessment and interpretation of craving relevant variables. Addiction, 2000, 95 (2), pp. 177–187.
15. United Nations Office on Drugs and Crime. World Drug Report 2014. United Nations publication, Sales No.E.14.XI.7, pp.51-55.
16. Valeriani G., Corazza O., Bersani F.S., Melcore C., Metastasio A., Bersani G., Schifano F. Olanzapine as the ideal "trip terminator"? Analysis of online reports relating to antipsychotics' use and misuse following occurrence of novel psychoactive substance-related psychotic symptoms. Hum Psychopharmacol. 2015, 30(4), pp. 249-254.
Библиографическая ссылка
Прилуцкая М.В., Берсани Ф.С. Профиль симптомов патологического влечения при расстройстве вследствие употребления «Соли для ванн»: клинический случай / / Наука и здравоохранение. 2016. №3. с. 135-140
Prilutskaya M., Bersani F.S. The craving symptom profile of “Bath salts” use disorder: a clinical case. Nauka i Zdravookhranenie [Science & Healthcare]. 2016, 3, pp. 135-140.
Прилуцкая М.В., Берсани Ф.С. Симптоматологиялық профилдің патологиялық нәсіптердің жаңа психоактивтың «Ваннаға арналған тұздардың» тәуелділігі (клиникалық жағдай) // Ғылым және Денсаулық сақтау. 2016. №3. Б. 135-140.